<DOC>
	<DOCNO>NCT00544128</DOCNO>
	<brief_summary>A non-inferiority randomize control trial treatment naïve HIV patient compare virologic effect two backbone regimen Epzicom ( lamivudine abacavir ) Truvada ( emtricitabine tenofovir ) . Both arm treat fixed combination ritonavir boost atazanavir key drug .</brief_summary>
	<brief_title>Comparison Epzicom Truvada Initial Once Daily HIV Treatment</brief_title>
	<detailed_description>In treatment naïve HIV-1-infected patient , daily combination antiretroviral therapy contain ritonavir boost atazanavir combine Epzicom offer non inferior antiretroviral efficacy compare ritonavir boost atazanavir combine Truvada . This non inferiority hypothesis study randomize , open label , multicenter trial 48 week primary endpoint long term safety arm follow 144 week . The primary endpoint antiretroviral effect 48 week . The secondary endpoint ; 1 . The immunologic effect baseline 48th 144th week 2 . Reasons treatment failure 144th week 3 . Adverse event rate incidence 144th week 4 . Serum concentration tenofovir select patient 5 . Serum concentration atazanavir select patient 6 . Renal complication tenofovir arm</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Clinical diagnosis HIV infection , Antiretroviral initiation recommend current clinical guideline , Treatment naïve , Age 20 year old Japanese , Able obtain write informed consent Current malabsorption condition , Prior use lamivudine hepatitis B treatment , Positive serology Hepatitis B surface antigen , Patients follow abnormal laboratory result within 6 week prior enrollment ; 1. alanine aminotransferase 2.5 time high upper normal limit 2. estimate glomerular filtration rate le 60ml/min CockcroftGault equation 3. serum phosphate level le 2.0mg/dl Patients hemophilia , diabetes mellitus require pharmacological treatment , congestive heart failure , cardiomyopathy serious medical condition Patients pregnancy breat feed Patients take medication contraindicate combine use study medicine Patients whose primary care physician consider inadequate enroll study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>initial therapy</keyword>
	<keyword>daily</keyword>
	<keyword>randomize trial</keyword>
	<keyword>non inferiority</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>